Miguel A. Fandino-Quintela

Almagro, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

FASN targeting by G28UCM impairs mitochondrial fatty acid synthesis and reveals a FASN-SDHB synthetic interaction.

FASN targeting by G28UCM impairs mitochondrial fatty acid synthesis and reveals a FASN-SDHB synthetic interaction.

Journal: Pharmacological research

Published: October 31, 2025

A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer.

A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer.

Journal: Cancer research communications

Published: July 25, 2025

Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations.

Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations.

Journal: NPJ precision oncology

Published: May 20, 2025

The automated computational workflow QUICHE reveals structural definitions of antitumor responses in triple-negative breast cancer.

The automated computational workflow QUICHE reveals structural definitions of antitumor responses in triple-negative breast cancer.

Journal: Nature cancer

Published: April 02, 2025

Correction: Applicability of epigenetic age models to next-generation methylation arrays.

Correction: Applicability of epigenetic age models to next-generation methylation arrays.

Journal: Genome medicine

Published: December 03, 2024

The impact of a high fat diet and platelet activation on pre-metastatic niche formation.

The impact of a high fat diet and platelet activation on pre-metastatic niche formation.

Journal: Nature communications

Published: August 05, 2024

Applicability of epigenetic age models to next-generation methylation arrays.

Applicability of epigenetic age models to next-generation methylation arrays.

Journal: Genome medicine

Published: June 10, 2024

High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer.

High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 14, 2024

Osteopontin mediates acquired resistance to hypoxia-inducing antiangiogenics and promotes anti-PD-L1 refractoriness in breast cancer models.

Osteopontin mediates acquired resistance to hypoxia-inducing antiangiogenics and promotes anti-PD-L1 refractoriness in breast cancer models.

Journal: The Journal of clinical investigation

Published: February 01, 2024

Distribution of PD-L1, TROP2 and HER2- "lowness" in early triple-negative breast cancer: an opportunity for treatment de-escalation.

Distribution of PD-L1, TROP2 and HER2- "lowness" in early triple-negative breast cancer: an opportunity for treatment de-escalation.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 21, 2023

Predicting resistance to chemotherapy using chromosomal instability signatures.

Predicting resistance to chemotherapy using chromosomal instability signatures.

Journal: Nature genetics

Published: July 21, 2023

Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement.

Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement.

Journal: EClinicalMedicine

Published: February 27, 2023

Showing 1-12 of 51

Last Updated: 09/26/2026